GE HealthCare reported a 3% increase in revenue in its second quarter of 2025, citing in part increasing demand for its nuclear medicine radiopharmaceuticals.
For the period (end-30 June), the company had revenues of $5 billion (€4.3 billion) compared with $4.84 billion (€4.2 billion) in the same period last year. Revenue growth was driven by strength in the U.S. and Europe, the Middle East, and Africa, the company said.
Net income attributable to GE HealthCare was $486 million (€425 million) versus $428 million (€374 million) for the prior year, while its adjusted earnings before interest and taxes (EBIT) were $729 million (€637 million) versus $742 million (€649 million) in the same period last year.
On an individual segment basis, GE HealthCare posted revenues of $2.204 billion (€1.927 billion) for its Imaging segment, up 2% from $2.171 billion (€1.899 billion) in the same period last year. The company’s Pharmaceutical Diagnostics segment had revenues of $729 million (€637 million), up 14% over the same period last year. The company noted it saw increased demand for its radiopharmaceutical products, including Vizamyl, Cerianna, and Flyrcado, and that it secured its largest-ever order of Omni Legend PET systems in the U.S.
“We also reported strong earnings performance while leveraging our lean capabilities and demonstrating progress on tariff mitigation,” said President and CEO Peter Arduini in a statement.
